Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

NEW YORK - Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reported fourth quarter revenue of $1.33 million, sending shares down 3.9% in after-hours trading. The clinical-stage biotechnology company ...

On Wednesday, Stifel analyst Alex Thompson reaffirmed a Buy rating on Dianthus Therapeutics (NASDAQ:DNTH) with a steady price target of $52.00. The endorsement follows the company’s fourth ...

On Wednesday, Stifel analyst Alex Thompson reaffirmed a Buy rating on Dianthus Therapeutics (NASDAQ:DNTH) with a steady price target of $52.00. The endorsement follows the company’s fourth-quarter ...

March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics ...